Effectiveness of biological disease-modifying antirheumatic drugs in progressive pulmonary fibrosis associated with rheumatoid arthritis
Clicks: 1
ID: 325406
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #195 of 198 articles by views in Lara D. Veeken
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 198 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Objectives To evaluate the effectiveness and safety of biological disease-modifying antirheumatic drugs (bDMARDs) in rheumatoid arthritis (RA)-associated progressive pulmonary fibrosis (PPF). Methods Real-world data were retrospectively collected in RA-associated PPF during the first year after bDMARD initiation. The primary outcome was change in pulmonary function and computed tomography (CT) visual scores at week 52. The secondary outcomes included comparisons of pulmonary function, CT scores, Clinical Disease Activity Index (CDAI), drug retention rates, and adverse event rates over 52 weeks among the tumour necrosis factor inhibitor (TNFi), cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin (CTLA4-Ig), and interleukin-6 receptor inhibitor (IL-6Ri), using propensity score–based inverse probability of treatment weighting (PS-IPTW). Results Among 2,484 patients with RA initiating bDMARDs, 443 had RA-associated interstitial lung disease (ILD), and 135 had RA-associated PPF (TNFi, n = 35; CTLA4-Ig, n = 45; IL-6Ri, n = 55). Treatment with bDMARDs markedly improved CDAI at week 52, and pulmonary function and CT scores remained stable. PS-IPTW-adjusted comparisons showed no significant differences in CDAI, CT scores, or drug retention rates among the bDMARD groups. However, forced vital capacity (FVC) improved in IL-6Ri compared with TNFi (−3.2% vs + 3.3%, p = 0.011; Cohen’s d = 0.630). Adverse events were less frequent in CTLA4-Ig. Multivariate logistic regression analysis identified IL-6Ri treatment, non-usual interstitial pneumonia (UIP) pattern, and lower CDAI at week 52 as independent predictors of FVC improvement. Conclusions Tight control of RA disease activity with bDMARDs appears crucial in RA-associated PPF. In this real-world comparative study, IL-6Ri may have contributed to improved FVC, whereas CTLA4-Ig may have a favourable safety profile.
| Reference Key |
openalex_W7203836292
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Ryuichiro Kanda, Yoshiya Tanaka, Yusuke Miyazaki, Satoshi Kubo, Midori Ueno, Takako Kawaguchi, Shunsuke Fukuyo, Ippei Miyagawa, Ayako Yamaguchi, Yurie Satoh-Kanda, Naoaki Ohkubo, Yasuyuki Todoroki, Masanobu Ueno, Yuya Fujita, Katsuhide Kusaka, Hidenori Sakai, 峻平 小坂, Satsuki Matsunaga, H Nohara, Kazuhiro Yatera, Takatoshi Aoki, Shingo Nakayamada |
| Journal | Lara D. Veeken |
| Year | 2026 |
| DOI |
10.1093/rheumatology/keag421
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.